Patents by Inventor Szilard Kiss

Szilard Kiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating CMV retinitis by T cell therapy
    Patent number: 11103577
    Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof comprise administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: August 31, 2021
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
  • METHODS OF TREATING OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT
    Publication number: 20210100856
    Abstract: Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.
    Type: Application
    Filed: September 10, 2020
    Publication date: April 8, 2021
    Inventors: Mehdi GASMI, Szilard KISS, Aaron OSBORNE, Adam TURPCU
  • Methods of Treating CMV Retinitis by T Cell Therapy
    Publication number: 20200016261
    Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.
    Type: Application
    Filed: May 23, 2019
    Publication date: January 16, 2020
    Applicants: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
  • Methods of treating CMV retinitis by T cell therapy
    Patent number: 10342864
    Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: July 9, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
  • Methods of Treating CMV Retinitis by T Cell Therapy
    Publication number: 20170128565
    Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.
    Type: Application
    Filed: June 24, 2016
    Publication date: May 11, 2017
    Applicants: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
  • VIRUS-MEDIATED DELIVERY OF BEVACIZUMAB FOR THERAPEUTIC APPLICATIONS
    Publication number: 20150182638
    Abstract: The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Donald Joseph D'Amico, Julie Boyer, Szilard Kiss
  • VIRUS-MEDIATED DELIVERY OF BEVACIZUMAB FOR THERAPEUTIC APPLICATIONS
    Publication number: 20130090375
    Abstract: The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.
    Type: Application
    Filed: June 29, 2012
    Publication date: April 11, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Donald Joseph D'Amico, Julie Boyer, Szilard Kiss